U.S. allows alternate monkeypox vaccine injection method to boost supply
Send a link to a friend
[August 10, 2022]
By Ahmed Aboulenein and Ankur Banerjee
WASHINGTON (Reuters) -U.S. health
regulators have authorized injecting a monkeypox vaccine intradermally
in adults, meaning between layers of the skin rather than below the
skin, in an effort to stretch out low vaccine supplies, the U.S. Food
and Drug Administration (FDA) announced on Tuesday.
The emergency use authorization for Bavarian Nordic's Jynneos monkeypox
vaccine will increase available doses fivefold as it only uses a
fraction of the dose but provides the same protection, health officials
said at a White House briefing.
The FDA authorization comes after the United States and the World Health
Organization declared monkeypox a public health emergency to bolster the
response against the outbreak.
Jynneos was approved in 2019 for smallpox and monkeypox prevention in
high risk adults 18 years of age and older. Under its original approval
it was to be administered beneath the skin beneath the skin, or
subcutaneously, as two doses.
Two doses of the vaccine given four weeks apart will still be needed
with the intradermal method, the agency said.
The FDA approval also allows people under 18 years to receive the
vaccine by subcutaneous injection if they are determined to be at high
risk of monkeypox infection. The FDA is staying with this method for
children as it is easier to administer and there is not as much data
available.
So far, 80 countries where the virus is not endemic have reported a
total 26,500 monkeypox cases, according to a Reuters tally.
There have been 8,900 cases of monkeypox reported in the United States
since the first case was recorded on May 18, Secretary of Health and
Human Services Xavier Becerra said.
[to top of second column]
|
A vial of the Jynneos vaccine is seen at Spallanzani hospital, as
vaccinations against monkeypox began in Rome, Italy, August 8, 2022.
Spallanzani Hospital/Handout via REUTERS
Administering the vaccine requires a different type of needle than
the current shot administration and is similar to the tuberculin
skin tests (or PPD) or intradermal allergy tests.
The U.S. Centers of Disease Control and Prevention will be providing
information and educational materials aimed at training health care
workers and providers on how to administer the vaccine intradermally,
CDC Director Rochelle Walensky said.
So far, the administration has made more than 1.1 million vaccine
doses available to order and has shipped more than 620,000 doses,
said Becerra.
There are 441,000 vials currently in the strategic national
stockpile and therefore over 2.2 million doses under the new
administration method, said Dawn O'Connell, assistant secretary for
preparedness and response at the Department of Health and Human
Services.
Britain will run out of monkeypox vaccines in about two to three
weeks as the country has little more than 8,300 doses of vaccine
left, the Financial Times reported on Tuesday.
(Reporting by Ahmed Aboulenein in Washington and Ankur Banerjee in
Bengaluru; Additional reporting by Rami Ayyub in Washington; Editing
by Aditya Soni and Josie Kao)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|